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Abstract
The Ca2+ sensor S100A1 is essential for proper endothelial cell (EC) nitric oxide (NO) synthase (eNOS) activation. S100A1
levels are greatly reduced in primary human microvascular ECs subjected to hypoxia, rendering them dysfunctional.
However mechanisms that regulate S100A1 levels in ECs are unknown. Here we show that ECs transfected with a S100A1–39
untranslated region (UTR) luciferase reporter construct display significantly reduced gene expression when subjected to low
oxygen levels or chemical hypoxia. Bioinformatic analysis suggested that microRNA -138 (MiR-138) could target the 39UTR of
S100A1. Patients with critical limb ischemia (CLI) or mice subjected to femoral artery resection (FAR) displayed increased
MiR-138 levels and decreased S100A1 protein expression. Consistent with this finding, hypoxia greatly increased MiR-138
levels in ECs, but not in skeletal muscle C2C12 myoblasts or differentiated myotubes or primary human vascular smooth
muscle cells. Transfection of a MiR-138 mimic into ECs reduced S100A1–3 ‘UTR reporter gene expression, while transfection
of an anti MiR-138 prevented the hypoxia-induced downregulation of the reporter gene. Deletion of the 22 nucleotide
putative MiR-138 target site abolished the hypoxia-induced loss of reporter gene expression. Knockdown of Hif1-a
mediated by siRNA prevented loss of hypoxia-induced reporter gene expression. Conversely, specific activation of Hif1-a by
a selective prolyl-hydroxylase inhibitor (IOX2) reduced reporter gene expression even in the absence of hypoxia. Finally,
primary ECs transfected with a MiR-138 mimic displayed reduced tube formation when plated onto Matrigel matrix and
expressed less NO when stimulated with VEGF. These effects were reversed by gene transfer of S100A1 using recombinant
adenovirus. We conclude that hypoxia-induced MiR-138 is an essential mediator of EC dysfunction via its ability to target the
39UTR of S100A1.
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Introduction
Lack of agonist-induced eNOS activation leads to endothelial
dysfunction and predisposes to a host of cardiovascular pathologies
[1]. We have recently identified the small EF-hand Ca2+ binding
protein S100A1 as part of an important molecular toolkit that
relays intracellular Ca2+ oscillations and regulates vascular tone.
Patients with critical limb ischemia (CLI) are known to have
impaired vasodilatory responses [2], and present with greatly
reduced levels of S100A1 in ischemic muscle tissue [3]. We were
able to show that S100A1 directly interacts with eNOS, prevents
PKC-mediated phosphorylation of the inhibitory Thr-495 site on
eNOS and augments eNOS enzymatic activity in ECs [3]. Loss of
S100A1 attenuates induction of angiogenesis in response to acute
tissue ischemia, thereby preventing relief of tissue malperfusion.
Thus mice genetically deficient in S100A1 suffer limb loss when
subjected to femoral artery resection (FAR) [3]. S100A1 levels in
ECs are rapidly lost upon exposure to hypoxia and this correlates
with a loss of stimulus-induced NO production [3]. Given the
importance of S100A1 to the regulation of eNOS activity and
overall EC physiology, we set out to investigate ischemia-induced
mechanisms that regulate S100A1 expression levels in ECs. Rapid
downregulation of S100A1 specifically in ECs suggested existence
of post-transcriptional regulatory mechanisms, possibly involving
microRNAs (MiRs). MiRs are short, <22 nucleotide long
regulatory RNAs that suppress gene expression by binding to
the 39 untranslated region (39UTR) of target mRNAs, inhibiting
their translation and/or augmenting mRNA degradation [4].
Here we report that MiR-138 targets the 39UTR of S100A1 and
regulates its expression in a hypoxia-dependent manner specifi-
cally in ECs.
Methods
Ethics Statement
Collection of patient biopsy specimen: Patients gave their
written informed consent to participate in the study, as described
[3]. The study protocol had been approved by the ethics
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committee of the Medical Faculty at the Technische Universita¨t
Dresden.
Animal experiments: All experiments were performed according
to protocols approved by the Institutional Animal Care And Use
Committee (IACUC) of Thomas Jefferson University and com-
plied with the Guide for the Care and Use of Laboratory Animals.
Mice
C57Bl/6 (WT) mice were purchased from Jackson Labs (Bar
Harbor, ME stock # 664).
Femoral Artery Resection (FAR)
Induction of acute limb ischemia by FAR was done as we
described earlier [3]. Briefly, mice were anesthetized with avertin,
and about 10 mm of the right common femoral artery distal of the
inguinal ligament was resected. All branches were carefully
cauterized. Care was taken to prevent nerve damage.
Patient Muscle Biopsy Samples
Characteristics of patients with CLI or control have been
described in detail [3].
Cell Culture
EA.hy926 endothelial cells ATCC (CRL-2922) were cultured in
DMEM (4.5 g/L glucose) supplemented with 10% FBS. Human
microvascular endothelial cells (HMVEC) were purchased from
Lonza (CC-7030) at passage 4–5 and cultured in ATCC vascular
cell basal medium (PCS-100-030) supplemented with the ATCC
endothelial cell VEGF growth kit (PCS-100-041). Human vascular
smooth muscle cells were purchased from the ATCC (PCS-100-
012) (Manassas, VA) and cultured in ATCC vascular cell basal
medium, supplemented with ATCC vascular smooth muscle cell
growth kit (PCS-100-042).
For induction of gas hypoxia cells were subjected for 24 h to 1%
O2 using a BioSpherix hypoxia chamber and ProOx C21 oxygen
controller. For chemical hypoxia cells were treated for 24 h with
either CoCl2 (250 mmol/L) or Desferroxamine (Des, 100 mmol/L)
or the specific prolyl hydroxylase-2 (PHD2) inhibitor IOX2, (N-
[[1, 2- dihydro- 4- hydroxy- 2- oxo- 1- (phenylmethyl)- 3-
quinolinyl]carbonyl]- glycine, Cayman Chemical) [5] at
10 mmol/L. Viability of EA.hy926 ECs or primary human ECs
was not compromised at CoCl2 concentrations less than 1 mmol/
L and Desferroxamine less than 250 mmol/L for 24 h (not shown).
Murine C2C12 myoblast cells (ATCC, cat # CRL-1772) were
cultured in DMEM supplemented with 10% FBS 1% Penicillin/
Streptomycin. Upon reaching confluency, cells were induced to
differentiate into myotubes by incubation for 5 days in 2% horse
serum, followed by treatment with CoCl2 (250 mmol/L) for 24 h
before extract preparation.
Plasmid
All luciferase reporter constructs were purchased from Switch-
Gear Genomics (Menlo Park, CA). The 39UTR reporter construct
of S100A1 gene (cat # S801348) comprised the 39UTR of the
human S100A1 gene cloned downstream of a constitutive
ribosomal protein L10 (RPL10) promoter and renilla luciferase
gene. The hypoxia reporter plasmid of the P4HA2 gene promoter
(cat # S721928) was used to confirm the induction of hypoxia.
39UTR control plasmid (cat # S804753) with SV40 T antigen
39UTR and b-actin control plasmid (cat # S717678) with b-actin
promoter were used as controls for transfection efficiency. A
39UTR control reporter having the same promoter (RPL10) but
linked to the SV40 T antigen 39UTR gave high expression, that
did not decrease upon treatment with gas or chemical hypoxia,
while a hypoxia reporter construct that employed the P4HA2
promoter and SV40-39UTR displayed about 4.8 (61.2) fold
induction upon exposure to CoCl2 (not shown). A gene block
(IDT) comprising the entire S100A1 39UTR, but lacking
specifically the 22 nucleotide putative MiR-138 target site, was
subcloned NheI to XhoI into the luciferase reporter vector to
generate the DMiR-138 construct. All constructs were verified by
sequencing using Jefferson’s genomics facility.
Transfection
EA.hy926 ECs were cultured in 24 well plates in DMEM with
10% FBS. Cells were transfected with 1 mg of luciferase reporter
constructs mixed with Lipofectamine 2000 in serum-free DMEM,
according to the manufacturer’s instruction (Life Technologies).
Transfection media was changed after 2–3 hours and replaced
with DMEM,10% FBS. Cells were harvested 40 h after transfec-
tion. Primary HMVEC cells were transfected in DMEM with 20
nmoles microRNA mimic (Dharmacon ThermoFisher, cat # C-
300605-05-0005) or Control mimic (cat # CP-004500-01-05) and
media was changed after 1–2 hours. Hif1-a siRNA was purchased
from SantaCruz (Dallas, TX, cat # SC-35561). To inhibit activity
of microRNA-138, 40 nmoles of a hairpin antimir (Dharmacon
ThermoFisher cat # IH-300605-0005) to MiR-138 was transfect-
ed into EA.hy926 cells using Lipofectamine 2000 (Invitrogen).
Alternatively, in some experiments we used a cholesterol-
conjugated antagomir-138 (1 mmol/L) to inhibit MiR-138 [6].
Real Time PCR for MiR-138 Expression in Mice
RNA was isolated from mice as well as cell samples using
RNAzol RT according to manufacturer’s instruction (MRC, Inc
cat# RN190). 1 mg of input RNA was used to reverse transcribe
cDNA using Origene (Rockville, MD) kit (cat # HP100042).
Human miR-138 real time PCR primer pair (cat # HP300151)
was from Origene which consisted of a universal primer- 59-
CTCTATGCGTCTGTACAAG-39 and microRNA primer 59-
AGCUGGUGUUGUGAAUCAGGCCG-39. Quantitative real
time PCR was performed using BioRad (Hercules,CA) SYBR
Green master mix and a Stratagene (La Jolla, CA) real time PCR
cycler. Expression of U6 RNA was used to normalize the
expression of miR-138. Characteristics of patients with CLI or
control have been described. [3] RNA was isolated from these
patient’s gastrocnemius muscle samples using RNAzol. qPCR for
miR-138, snoRD44 and snoRD47 was done using ABM (Applied
Biological Materials, Inc, Richmond, BC Canada) primers
MPH01156, MPH00003 and MPH00004, respectively using
manufacturer’s instruction.
Luciferase Assays
Light Switch luciferase assay reagents (cat # LS100) were from
SwitchGear Genomics. ECs were cultured and transfected in 24
well plates. To measure luciferase expression, 100 ml of assay
reagents were added to each well and enzyme activity was
measured, according to the manufacturer’s instruction (Switch-
Gear Genomics) using a Wallac Victor3 Multilabel counter (Perkin
Elmer, MA). Luciferase expression is given as relative light units
(RLU). All luciferase experiments were done in triplicate and
repeated a minimum of 3 times.
Immunoblot Assay
Cell samples were lysed in Laemmli buffer and 30 mg/Lane
whole cell extract was loaded on 4–20% Tris-Glycine gel, (Life
Technologies, CA) and transferred to nitrocellulose membrane.
MiR-138 Targets S100A1
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Membranes were probed for S100A1 (Acris, San Diego, CA, cat
# SP5355P, b-actin (SantaCruz cat # sc-8432), Hif1-a (Santa-
Cruz cat# sc-10790) total eNOS (BD Biosciences cat# 610297) or
phospho Thr-495 eNOS (BD Biosciences cat# 612707). Protein
expression was quantitatively assessed using an Odyssey scanner
(Li-Cor Biosciences, Lincoln NE). All immunoblot assays were
done in duplicate and repeated a minimum of three times.
Matrigel Tube Formation Assay
Growth-factor reduced Matrigel Matrix (BD Biosciences, cat#
356231) was diluted 1:1 with ATCC vascular cell basal medium
(no additives). HMVEC (approx 200,000 cells) were transfected
with MiR-138 mimic or scramble control. 48 h later cells were
infected with recombinant Adenovirus expressing S100A1 and
GFP from a bicistronic insert [7], or control at an multiplicity of
infection (MOI) of 17. After 24 h cells were detached from the
plastic support with trypsin and seeded onto the Matrigel matrix in
medium consisting of 9 parts ATCC medium and 1 part ATCC
medium containing ATCC endothelial cell VEGF growth kit
(PCS-100-041). Images were taken 24 h later and digitized using
NIH-ImageJ software. Original images of the matrigel tube
formation assays are included as online supplement Figure S3.
Nitric Oxide Assay
HMVEC (approx 100,000 cells) were transfected with MiR-138
mimic or scramble control. 48 h later cells were infected with
recombinant Adenovirus expressing S100A1 and GFP from a
bicistronic insert, or control at a MOI of 17. 8 h later the infection
medium was removed and cells were starved overnight in ATCC
vascular cell basal medium supplemented with 0.2% FBS. NO
production was then stimulated with the addition of 50 ng/ml
VEGF (R&D systems). Medium was collected 24 h later and NO
levels were measured using a fluorescent NO/Nitrite/Nitrate
assay (Cayman Chemical, cat# 780051) according to manufac-
turer’s instructions.
Statistical Analysis
One-way ANOVA with Tukey posttest for multiple compari-
sons was used to analyze the appropriate data using GraphPad
PRISM software. Data are shown as 6 SEM in the figures. A P
value of ,0.05 was considered statistically significant. All
experiments were done independently a minimum of three times.
Each set-up was done at least in duplicate for each repetition.
Results
The 39UTR of the S100A1 mRNA Regulates S100A1 Gene
Expression
The rapid ischemia-induced downregulation of S100A1 that we
observed in both human and mouse ECs [3], suggested possible
involvement of post-transcriptional regulatory mechanisms.
S100A1 protein expression in primary human microvascular
ECs is drastically repressed by chemical hypoxia (CoCl2,
250 mmol/L, Figure 1A), the rapidity of which suggested
involvement of post-transcriptional mechanisms, possibly involv-
ing micro-RNAs (MiRs). MiRs typically bind to the 39UTR of
target mRNAs, repressing their translation or leading to their
degradation [4]. In order to specifically examine the role of the
39UTR in the potential regulation of S100A1 protein expression,
we assessed expression of a S100A1-39UTR luciferase reporter
gene in human EA.hy926 ECs, subjected to low oxygen (1%O2) or
chemical hypoxia (CoCl2 or Desferroxamine, Des). Reporter gene
expression was reduced to about 25% of that observed in
normoxic cells, regardless whether chemical hypoxia or low
oxygen was used (Figure 1B). A control reporter gene having the
same promoter (from the ribosomal protein 10) but linked to the
SV-40-39UTR gave high expression, that did not decrease upon
treatment with low oxygen or chemical hypoxia (data not shown).
In addition, EA.hy926 ECs transfected with a hypoxia reporter
construct that employed the P4HA2 promoter and SV-40-39UTR
displayed about 4.8 (61.2) fold induction upon exposure to CoCl2
(data not shown). Reduction of S100A1–39UTR reporter gene
expression was dose dependent for treatment with both CoCl2 and
Desferroxamine (Des, Figure S1). Importantly, viability of the
EA.hy926 was not compromised at concentrations of CoCl2 less
than 1 mmol/L and of Desferroxamine less than 250 mmol/L for
24 h (not shown).
MiR-138 Targets the S100A1-39UTR in ECs
Regulation of gene expression by the 39UTR suggested possible
involvement of a regulatory microRNA [4]. The 39UTR of
S100A1 is relatively short (196 bases for the human and 186 bases
for the murine isoform). Since both human and murine S100A1
genes appear subject to the same degree of hypoxia-induced
downregulation [3], we reasoned it likely that a conserved micro
RNA would target a species-conserved region of the 39UTR.
Using MiRanda (at microrna.org) [8] we conducted a database
search for conserved micro RNAs that would target both the
human and mouse S100A1 39UTR. The only micro RNA that
registered a ‘‘hit’’ for S100A1–39UTR of both species was
microRNA–138 (MiR-138). This micro RNA is encoded by two
different intergenic loci on chromosomes 3 and 16 for hsa-MiR-
138-1 and hsa-MiR-138-2 respectively (mouse chromosomes 9
and 8 resp.). Deep sequencing reads overwhelmingly detect only
the 5p segment of both MiR-138-1 and MiR-138-2 [9,10]. The
mature MiR-138 is conserved between human and mouse and
alignment of the human and mouse S100A1–39UTRs with MiR-
138 shows the binding site of this micro RNA to be in the most
conserved region of the 39UTR (95% identical) whereas the rest of
the S100A1-39UTR shares ,70% identity between the two
species (Figure S2). Indeed hypoxia (induced by either low oxygen
or chemical reagents) drastically increased expression of MiR-138
in both EA.hy926 as well as primary microvascular ECs
(HMVEC, Figure 1C).
In order to verify the potential targeting of S100A1 by MiR-
138, we co-transfected a MiR-138 mimic (Dharmacon) together
with the S100A1–39UTR reporter into EA.hy926 cells. The MiR-
138 mimic reduced reporter gene expression by over 95% after
24 h (Figure 2A). When transfected into primary HMVECs the
mimic significantly reduced S100A1 protein levels (Figure 2B),
reminiscent of that achieved by chemical hypoxia (Figure 1A),
while transfection with a scrambled control mimic did not change
reporter gene expression. Confirmation of the role of MiR-138 in
the regulation of S100A1 was obtained by deleting the putative 22
nucleotide MiR-138 target site within the S100A1–39UTR of the
luciferase reporter. This construct (DMiR-138), in all other
elements identical to the wild-type (WT) S100A1–39UTR
reporter, showed no reduction of gene expression when transfected
into EA.hy926 cells subjected to chemical hypoxia (Figure 2C).
We next determined whether the hypoxia-induced increase in
MiR-138 was cell type selective with regard to other cell types
relevant to muscle physiology. Neither skeletal muscle myoblasts,
differentiated myotubes (Figure 3), nor primary human vascular
smooth muscle cells (HVSMCs, Figure 4) display much of a
change of S100A1 or MiR-138 expression when subjected to
hypoxia, even though all of these cell types express both S100A1
and MiR-138. These findings agree with our previous study that
demonstrated significant differences in hypoxia-induced attenua-
MiR-138 Targets S100A1
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Figure 1. Hypoxia reduces S100A1 gene expression in
Endothelial cells via its -39UTR. A) Primary human microvascular
endothelial cells (HMVECs) were subjected to chemical hypoxia by
treatment with CoCl2 (250 mmol/L) for 24 h before extract preparation
and immunoblot analysis. Expression levels of S100A1 were quantitated
using a LICOR Odyssey near infrared scanner and normalized to those of
b-actin. The experiment was done 4 times, each in duplicate. *,
P,0.05 vs normoxic. B) EA.hy926 ECs were transfected with the
S100A1–39UTR luciferase reporter and subjected to chemical (CoCl2 or
Desferroxamine (Des) or gas hypoxia (1% O2), for 24 h. Luciferase
expression was measured as described in the Methods section and
presented as relative light units (RLU) normalized to untreated cells. *,
P,0.02 vs untreated normoxic. The experiment was performed 4 times,
each in triplicate. Expression of a luciferase reporter linked to a control
39UTR (from SV40 T antigen) was not changed (not shown). C)
Expression of MiR-138 was measured by qPCR in EA.hy926 ECs or
primary HMVECs treated with 1% O2 or CoCl2 (250 mmol/L) or
Desferroxamine (Des, 100 mmol/L) for 24 h. Levels of the small nuclear
RNA U6 were assessed in parallel and used to normalize expression. The
experiment was done 4 times, each in triplicate. *, P,0.01 vs untreated.
U6 expression did not change during hypoxia.
doi:10.1371/journal.pone.0078684.g001
Figure 2. MiR-138 decreases S100A1 gene expression in
Endothelial Cells. A) EA.hy926 ECs were co-transfected with the
S100A1–39UTR luciferase reporter gene and either a MiR-138 mimic or
scrambled control mimic. Luciferase activity in cell lysates was
measured 24 h later and is reported as relative light units (RLU)
normalized to untreated cells. *, P,0.01 vs ctr. mimic. The experiment
was done 3 times, each in triplicate. Expression of a luciferase reporter
linked to the control 39UTR was not changed by the mimic treatment
(not shown). B) Primary HMVEC were transfected with the MiR-138
mimic for 1 or 3 days or control mimic for 3 days. Cell extracts were
immunoblotted for S100A1 or b-actin (as loading control). Transfection
with the control mimic did not change S100A1 levels compared to
untransfected HMVECs (not shown). A representative immunoblot is
shown. The experiment was performed 3 times. Expression of S100A1
was normalized to b-actin. *, P,0.05 vs ctr. Mimic. C) EA.hy926 ECs
were transfected with either the wild-type (WT) S100A1–39UTR
luciferase reporter gene or a S100A1–39UTR with deletion of the 22
nucleotide putative MiR-138 target site (DMiR138). 24 h later cells were
MiR-138 Targets S100A1
PLOS ONE | www.plosone.org 4 November 2013 | Volume 8 | Issue 11 | e78684
tion of S100A1 expression between isolated murine skeletal muscle
myofibers and primary ECs [3].
In order to assess the physiological relevance of endogenously
produced MiR-138, we inhibited the function of endogenously
generated MiR-138 by incubating primary HMVECs with a
specific antagomir to MiR-138 [6]. Transfection of the antagomir-
138 completely prevented the loss of S100A1 protein expression,
while a scramble control antagomir had no effect on the hypoxia-
induced downregulation of S100A1 expression in HMVECs. This
indicates that hypoxia regulates S100A1 expression in ECs
predominantly via MiR-138 (Figure 5A). Confirmation of this
was also obtained by co-transfecting a hairpin anti-MiR-138
(antimir-138, Dharmacon) into EA.hy926 ECs together with the
S100A1-39UTR reporter. The antimir-138 completely prevented
the downregulation of the reporter gene induced by either low
oxygen or chemical hypoxia, while co-transfection with a
subjected to chemical hypoxia (250 mmol/L CoCl2). Luciferase activity in
cell lysates was reported as relative light units (RLU) normalized to WT
untreated cells. *, P,0.01 vs untreated. The experiment was done 3
times, each in triplicate.
doi:10.1371/journal.pone.0078684.g002
Figure 3. Hypoxia does not increase MiR-138 in skeletal muscle cells. Murine C2C12 skeletal myoblasts (left panels) or differentiated
myotubes (right panels) were subjected to hypoxia for 24 h. Protein extracts were immunoblotted for S100A1 protein expression (upper panels) and
expression of MiR-138 by qPCR (lower panels). Expression of Myosin Heavy Chain (MHC) was used to verify differentiation. Experiment was performed
3 times, each in duplicate. *, P,0.05 vs normoxic.
doi:10.1371/journal.pone.0078684.g003
MiR-138 Targets S100A1
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scrambled control antimir had no effect (Figure 5B). Together,
these findings strongly suggest that hypoxia induces cell-type
selective expression of MiR-138 and that this induction can
drastically reduce S100A1 protein levels in ECs.
MiR-138 is Increased in Critical Limb Ischemia
We had demonstrated greatly reduced S100A1 levels in mal-
perfused muscle tissue of both human patients with CLI and mice
after induction of limb ischemia by FAR [3]. In support of a
crucial role of MiR-138 in the regulation of endothelial S100A1
expression, we found that levels of MiR-138 were significantly
increased in samples taken from both human patients with CLI
(Figure 6A) and ischemic mouse gastrocnemius muscles
(Figure 6B), while expression of housekeeping small nucleolar
RNAs RD44 and RD47 did not change, demonstrating that tissue
ischemia leads to an increase in MiR-138 that could potentially be
responsible for the observed downregulation of S100A1. It is likely
that the majority of the observed increase in MiR-138 under this
pathological condition is attributable to the EC compartment,
given that both skeletal muscle cells as well as vascular smooth
muscle cells do not demonstrate a significant increase of MiR-138
when subjected to hypoxia (Figures 3, 4).
Hif1-a Activation is Required for the Hypoxia-induced
Expression of MiR-138
The hypoxia-induced increase in MiR-138 led us to examine
the contribution of the transcription factor hypoxia-induced factor
1-a (Hif1-a) to the regulation of MiR-138 expression. Specific
inhibition of the prolyl-hydroxylase 2 enzyme by IOX2 leads to
the stabilization of Hif1-a in endothelial cells [5] (Figure 7A), and
greatly increased MiR-138 levels (Figure 7B), concomitant with
reduced S100A1–39UTR reporter gene expression. This was
specifically due to the induction of MiR-138 since co-transfection
with the antimir-138 completely reversed the decrease in reporter
gene expression (Figure 7C). The critical role of Hif1-a in the
induction of MiR-138 in ECs was proven by siRNA-induced
Figure 4. Primary human vascular smooth muscle cells do not
change S100A1 nor MiR-138 levels during hypoxia. A) Primary
human microvascular smooth muscle cells (HVSMCs, obtained from the
ATCC) were subjected to hypoxia for 24 h. Protein extracts were
immunoblotted for Hif1-a (to verify induction of hypoxia), b-actin (to
verify equal loading), and S100A1. B) Expression of MiR-138 was by
qPCR. Experiment was performed 3 times, each in duplicate.
doi:10.1371/journal.pone.0078684.g004
Figure 5. Specific inhibition of MiR-138 prevents the hypoxia-
induced loss of S100A1 in ECs. A) Primary HMVECs were transfected
with the antagomir-138 (or control antagomir) and subjected to
chemical hypoxia (CoCl2, 250 mmol/L) for 24 h before extract prepara-
tion and immunoblot analysis. S100A1 expression was normalized to
that of b-actin. The experiment was done 3 times, each in duplicate. *,
P,0.05 vs control antagomir. B) EA.hy926 ECs were transfected with an
antimir-138 (or control) and subjected to either gas hypoxia (1% O2) or
chemical hypoxia (CoCl2, 250 mmol/L) for 24 h. Luciferase activity in cell
lysates was reported as relative light units (RLU) normalized to
untreated cells. The experiment was done 3 times, each in triplicate.
*, P,0.02 vs antimir-138 treated.
doi:10.1371/journal.pone.0078684.g005
MiR-138 Targets S100A1
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silencing of Hif1-a, which completely prevented the hypoxia-
induced downregulation of reporter gene activity (Figure 7D).
MiR-138 Induces EC Dysfunction Specifically via
Inhibition of S100A1
In order to examine the physiological relevance of increased EC
MiR-138 expression we transfected primary HMVEC with the
MiR-138 mimic and tested the ability of these cells to form
capillary-like tube networks on Matrigel matrix. Tube formation
was greatly reduced in MiR-138 mimic transfected cells,
coincident with greatly reduced levels of S100A1 (Figures 8A, B,
see Figure S3 for the original, non-digitized, photo-micrographs).
Infection with recombinant adenovirus expressing S100A1 [11] re-
established S100A1 levels to near normal in MiR-138 mimic
transfected cells (Figure 8B), and re-established tube formation
capability (Figure 8A). We had previously demonstrated that
S100A1 is an essential factor required for proper eNOS activation
in ECs [3,7]. While total eNOS levels remained unchanged in
MiR-138 mimic transfected ECs, the reduction of S100A1 greatly
increased eNOS phosphorylation on Thr-495, a demonstrated
eNOS inhibitory site [12] (Figure 8B). This change in eNOS
phosphorylation also was normalized upon re-expression of
physiologic levels of S100A1, even in the continued presence of
the MiR-138 mimic. Physiologically, the increased phosphoryla-
tion of Thr-495 induced by the MiR-138 mimic abolished VEGF
stimulated NO production in ECs (Figure 9). Restoration of
physiological levels of S100A1, even in the presence of MiR-138
mimic, normalized the VEGF-stimulated NO production
(Figure 9). Both capillary network formation on matrigel matrix
and stimulus induced NO formation are considered hallmarks of
healthy endothelial cell function. Since NO production contributes
to the pro-angiogenic actions of VEGF [13], these experiments
provide conclusive evidence for the pathophysiological relevancy
of increased MiR-138 expression and subsequent suppression of
S100A1 in ECs.
Figure 6. MiR-138 levels are increased in ischemic muscle
tissue. A) Gastrocnemius muscle biopsy specimens from patients with
CLI and non-ischemic control [3] were analyzed for expression levels of
MiR-138 and the housekeeping small nucleolar RNAs snoRD44 and
snoRD47 by qPCR. Expression levels are presented as fold CLI/normal.
n = 4; *, P,0.05 vs snoRD44 or 47, whose expression levels in CLI
samples were not significantly different from normal. B) Gastrocnemius
muscle biopsy specimens from mice post femoral artery resection (FAR)
and non-ischemic contralateral control were analyzed for expression
levels of MiR-138 and the U6 small nuclear housekeeping RNA by qPCR
at times indicated. Expression levels are presented as fold FAR/normal.
n = 4; * P,0.05 vs U6, whose expression levels in FAR samples were not
significantly different from normal.
doi:10.1371/journal.pone.0078684.g006
Figure 7. Hif-1a mediates the reduction of S100A1-39UTR
reporter gene expression. A) EA.hy926 (upper panel) or primary
HMVEC (lower panel) cells were exposed to the prolyl-hydroxylase-2
inhibitor IOX2 (10 mmol/L) for 24 h to induce Hif1-a, prior to extract
preparation. A representative immunoblot is shown to verify Hif1-a
induction. The experiment was done 3 times with similar results. b-actin
was used to control for protein loading. B) Expression levels of MiR-138
were assessed by qPCR in extracts prepared from EA.hy926 ECs
subjected to 24 h treatment with 10 mmol/L IOX2. C) EA.hy926 ECs
were co-transfected with the S100A1–39UTR luciferase reporter gene
and either the antimir-138 or scramble control (Dharmacon). 24 h later
cells were incubated with IOX2 to induce Hif1-a stabilization. *,
P,0.02 vs untreated. For both B, C, the experiment was done 3 times,
each in triplicate. D) EA.hy926 ECs were transfected with the S100A1-
39UTR reporter gene and co-transfected with siRNA against Hif1-a, or
control scramble siRNA. Cells were then subjected to chemical hypoxia
with 250 mmol/L CoCl2 for 24 h before luciferase activity was assessed.
*, P,0.02 vs normoxic, P,0.05 vs siRNA Hif1-a. Experiment was
performed 3 times, each in triplicate.
doi:10.1371/journal.pone.0078684.g007
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Discussion
Appropriate expression of S100A1 appears essential for correct
intracellular signaling in large variety of different cell types. On a
cellular level, S100A1 expression is highest in cardiomyocytes
where this Ca2+- binding EF-hand protein orchestrates the
complex Ca2+ fluxes required for optimal excitation–contraction
coupling [14], however this protein is also found in significant
quantities in skeletal muscle myofibers [15], neurons [16], and
ECs [3,7], amongst others. First evidence of an important
contribution of S100A1 to EC physiology was gleaned from the
hypertensive phenotype of S100A1 gene deficient mice, which
presented with impaired endothelium-dependent vasodilation [7].
Subsequently we showed that S100A1 is an essential activator of
eNOS and is required for post-natal vascular angiogenesis in
response to ischemia [3]. Pathophysiologic relevance may be
derived from the observation that S100A1 levels are severely
downregulated [3], while MiR-138 levels are increased, in both
human muscle biopsies procured from patients with CLI, as well
as mice with induced limb ischemia (Figure 6). It is now clear that
distinct regulatory mechanisms govern expression of S100A1 in
different cell types. First evidence of this was obtained in isolated
ECs and myofibers where hypoxia induces a rapid loss of S100A1
selectively in ECs [3].
Here we report, for the first time, on the mechanisms by which
S100A1 expression is selectively regulated in ECs (see Figure 10
for a proposed scheme). The most important finding of our work is
the identification of MiR-138 as a crucial determinant of S100A1
expression in ECs subjected to hypoxia. It is clear that MiR-138
itself is dynamically regulated in response to low oxygen levels in a
cell-type specific manner. It is tempting to speculate that one or
both of the MiR-138 genes may be direct targets of Hif1-a, since
we have shown here that this transcription factor is indispensable
for the hypoxia-induced expression of MiR-138 and the subse-
quent repression of S100A1. In this light it is interesting to note
that MiR-138 has been reported to directly target Hif1-a in
cultured cells [17,18], potentially allowing for feed-back control of
MiR-138 expression during hypoxia. However, we can not rule
out other ways by which MiR-138 expression is controlled since
processing of the mature MiR-138 from the pre-MiR-138 also
appears to be a regulated step in some tissues [19]. Furthermore it
is clear that hypoxia, per se, does not increase MiR-138 levels in all
cells, as we have shown that C2C12 skeletal muscle cells, while
expressing both MiR-138 and S100A1, do neither increase MiR-
138, nor decrease S100A1 when subjected to hypoxia. While a
recent report by Li et al. demonstrated a hypoxia-induced increase
of MiR-138 in airway smooth muscle cells [20], we did not observe
a significant hypoxia-induced change in either MiR-138 or
S100A1 expression in primary human vascular smooth muscle
Figure 8. MiR-138 compromises EC Matrigel-induced capillary
formation by inhibiting S100A1. A) Primary HMVEC were
transfected with the MiR-138 Mimic or scramble control Mimic. 48 h
later cells were infected (MOI = 17) with either control Adenovirus or
Adenovirus expressing S100A1. 24 h later cells were seeded onto
Matrigel matrix. Images of EC tube formation were taken 24 h later and
digitized using Image J (Original pictures of EC tube formation are
included as Figure S3). B) Cell extracts of HMVEC treated in parallel to
those in (A) were immunoblotted for S100A1, total or p-Thr 495 eNOS,
or b-actin (as loading control). Representative images are shown. The
experiment was done 3 times, each in duplicate. Expression levels of
S100A1 and pT-495 eNOS were normalized to b-actin and total eNOS,
respectively. The experiment was done 3 times, each in duplicate. *,
P,0.05 vs untreated.
doi:10.1371/journal.pone.0078684.g008
Figure 9. MiR-138 compromises VEGF-stimulated NO produc-
tion by inhibiting S100A1. Primary HMVEC cells treated in parallel to
those in Figure 8 were starved for 24 h in medium supplemented with
0.2% FBS before being treated with 50 ng/ml VEGF. Supernatants were
collected 24 h later and analyzed for nitrate/nitrite levels. The
experiment was done 3 times, in duplicate. *, P,0.01 vs no Mimic, #,
P,0.01 vs control Adenovirus. Re-expression of S100A1 reverses the
MiR-138 induced EC dysfunction.
doi:10.1371/journal.pone.0078684.g009
MiR-138 Targets S100A1
PLOS ONE | www.plosone.org 8 November 2013 | Volume 8 | Issue 11 | e78684
cells, however it is likely that the significant differences in smooth
muscle cell type (airway vs. microvascular) and the different species
(rat in the study by Li et al. vs human in ours) are at least partly
responsible for the observed differences.
MiR-138 has thus far been reported to be involved in a variety
of cellular functions related to cell motility [21] and control of
tumor growth [22,23,24,25]. While MiR-138, like all other
microRNAs, has a large number of potential targets, its
suppression of S100A1 in ECs may be especially important for
vascular physiology since we have shown here that restoration of
S100A1 levels in ECs with increased MiR-138 is sufficient to
reverse EC dysfunction, as manifest by restored stimulus-
dependent NO generation and Matrigel tube formation capability.
Conclusions
Here we show for the first time that S100A1, a central co-
activator of eNOS activity, is drastically downregulated by
hypoxia-induced MiR-138 in endothelial cells. Reduced eNOS
activity leads to accompanying increases in vascular risk factors
such as hypertension, vascular wall oxidative stress, increased
platelet aggregation and reduced ischemia-promoted angiogenesis
[1]. These manifestations of endothelial dysfunction are a hallmark
of most chronic cardiovascular diseases including peripheral
arterial disease. Patients with CLI, the most advanced form of
PAD, represent a significant unmet clinical challenge with overall
poor prognosis and limited options [26,27]. As strategies to
manipulate microRNA levels in vivo become more mature [6,28],
MiR-138 might represent an attractive target for the treatment of
pathologies that have underlying EC dysfunction.
Supporting Information
Figure S1 EA.hy926 ECs were transfected with the
S100A1-39UTR reporter gene and treated for 24 h with
the indicated doses of CoCl2 or Desferroxamine (Des).
Chemical hypoxia dose-dependently decreases S100A1 gene
expression. The experiment was done in triplicate and repeated
3 times. *, P,0.05 vs untreated.
(TIF)
Figure S2 A) Alignment of miR-138 with the human S100A1-
39UTR as predicted by miRANDA. The MiR seed region is
Figure 10. Proposed Scheme of S100A1 regulation by MiR-138. (1) Under normal oxygen tension, the transcription factor Hif1-a is
continuously hydroxylated by the action of cellular prolyl-hydroxylases (PHDs) in a reaction that requires Fe2+ and O2 as co-factors. (2) Hydroxylation
of Hif1-a promotes binding of the Von Hippel-Lindau (VHL)-E3 ubiquitin ligase complex, promoting poly-ubiquitination and (3) degradation via the
26S proteasome complex. The action of PHDs are inhibited directly by IOX2 and Cobalt and indirectly by iron chelators, such as Desferroxamine (Des)
as well as low oxygen levels. (4) Under low oxygen tension the Hif1-a protein becomes stabilized in the nucleus and promotes transcription of the
pro-angiogenic vascular endothelial growth factor (VEGF) gene. VEGF promotes activation of eNOS by signaling through VEGFR2, promoting
phosphorylation of the stimulatory Ser-1177 site. Increased eNOS activity raises nitric oxide (NO) production, which inhibits PHDs, further promoting
Hif1-a stabilization in a positive feed-back loop. (5) To maintain cellular homeostasis, stabilization of Hif1-a also promotes increased production of
MiR-138, (6) which binds to the 39UTR of the S100A1 mRNA, leading to drastically reduced S100A1 levels and reduction of eNOS activity by
promoting phosphorylation of the inhibitory Thr-495 site (7), in a counterbalancing negative feed-back loop. Endothelial dysfunction develops when
these carefully balanced multiple feedback loops become dysregulated allowing for prolonged MiR-138 expression with consequent loss of S100A1
and reduced eNOS activity.
doi:10.1371/journal.pone.0078684.g010
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boxed in red. B) Alignment of human and mouse S100A1-
39UTRs. The predicted miR-138 target region (deleted in the
DMiR138 construct) is outlined in red. Overall homology of the
39UTR is 72%, homology of the miR-138 target is 95% (21/22).
(TIF)
Figure S3 Original (not digitized) Matrigel tube forma-
tion images of those shown in Figure 8.
(TIF)
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